furiex pharmaceuticals
(FURX:Consolidated Issue Listed on Nasdaq Glbl Slct Mrkt)
As of 8:10 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).
Key Executives - furiex pharmaceuticals (FURX)
| Name | Board Relationships | Title | Age |
| June S. Almenoff M.D., Ph.D., F.A.C.P. | 6 Relationships | President, Chief Medical Officer and Director | 55 |
| Marshall H. Woodworth | No Relationships | Chief Financial Officer, Principal Accounting Officer, Treasurer and Assistant Secretary | 54 |
| Fredric N. Eshelman Pharm.D. | 49 Relationships | Executive Chairman, Vice Chairman of PPD and Chief Executive Officer of PPD | 63 |
| Paul S. Covington M.D. | No Relationships | Senior Vice President of Clinical Development and Operations | 56 |
| Gail F. McIntyre Ph.D., CH (ASCP), DABT | No Relationships | Senior Vice President of Research | 49 |
Board Members - furiex pharmaceuticals (FURX)
| Name | Board Relationships | Primary Company | Age |
| Fredric N. Eshelman Pharm.D. | 49 Relationships | Furiex Pharmaceuticals, Inc. | 63 |
| June S. Almenoff M.D., Ph.D., F.A.C.P. | 6 Relationships | Furiex Pharmaceuticals, Inc. | 55 |
| Wendy L. Dixon Ph.D. | 66 Relationships | Furiex Pharmaceuticals, Inc. | 57 |
| Robert P. Ruscher | 6 Relationships | Furiex Pharmaceuticals, Inc. | 52 |
| Peter B. Corr Ph.D. | 26 Relationships | Auven Therapeutics Management L.L.L.P | 64 |
Executive Committees* - furiex pharmaceuticals (FURX)
| Committee Name | Chairperson | Board Relationships | Members |
| Audit Committee | Robert P. Ruscher | 6 Relationships | 3 Executives |
| Compensation Committee | Peter B. Corr Ph.D. | 26 Relationships | 3 Executives |
| Nominating Committee | Wendy L. Dixon Ph.D. | 66 Relationships | 4 Executives |
| Corporate Governance Committee | Wendy L. Dixon Ph.D. | 66 Relationships | 4 Executives |
*Data is at least as current as the most recent Definitive Proxy.
| Recently Viewed | |||
| FURX:US | $38.13 USD | +1.38 |  |
| Company | Last | Change |
| AstraZeneca PLC | 3,383 GBp | -6.50 |
| Eli Lilly & Co | $55.90 USD | -0.04 |
| Merck & Co Inc | $45.99 USD | -0.38 |
| Novartis AG | SFr.71.75 CHF | -0.45 |
| Takeda Pharmaceutical Co Ltd | ¥4,955 JPY | -10.00 |
| View Industry Companies | ||
Industry Analysis
FURX
Industry Average
| Valuation | FURX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 4.8x |
|
| Price/Book | 7.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.8x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
Report Data Issue
To contact FURIEX PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Please enter your information in the following field(s):
Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
